SDC1 and neoplasm: Given the evaluation of cell surface PGs in clinical trials for different tumor settings, SDC family members appear to be important candidates for therapeutic targeting using monoclonal antibodies (given their plasma membrane expression), peptide inhibitors (to impede their interactions with integrins or RTKs), small molecule inhibitors, biomolecule mimetics (e.g., miRNAs and HMWHA), and HS mimetics (or their nanoformulations) or inhibitors for their exosomal packing.